Treatment Period and Long-term Efficacy of Functional Electrical Stimulation (FES) on Sleep Bruxism
This study has been terminated.
(The population described via ex- and inclusion criteria did not excisit)
Sponsor:
Medotech A/S
Information provided by:
Medotech A/S
ClinicalTrials.gov Identifier:
NCT01005511
First received: October 30, 2009
Last updated: June 7, 2011
Last verified: October 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To investigate the effect of the treatment with Grindcare® on the muscles- and jaw symptoms and at the jaw muscle activity during sleep.
| Condition | Intervention |
|---|---|
|
Bruxism |
Device: Grindcare Device: Grindcare - inactive |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Single Centre, Randomised, Clinical Placebo Controlled Study of the Optimal Treatment and Long-term Effect of FES on Sleep Bruxism |
Further study details as provided by Medotech A/S:
Primary Outcome Measures:
- Reduction in the electromyography (EMG) activity per hour per night [ Time Frame: 10 weeks after start of treatment ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Evaluation of long-term effect of FES on the EMG activity [ Time Frame: a 4 weeks period after end og treatment with FES ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 48 |
| Study Start Date: | October 2009 |
| Study Completion Date: | December 2010 |
| Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Grindcare
24 patients receiving active treatment
|
Device: Grindcare
Active treatment
|
|
Placebo Comparator: Placebo treatment
24 patients receive a placebo treatment
|
Device: Grindcare - inactive
Placebo treatment
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Signed and dated ICF
- 18 years or older
- Fulfill the RDC-criteria for myofascial TMD diagnose (group 1a or 1b)
Exclusion Criteria:
- Contraindication of concommitant diseases for the study judged by investigator
- Patients who are using occlusal splints in the treatment period.
Contacts and Locations
More Information
No publications provided
| Responsible Party: | Peter Svensson, Aarhus University Dentist School |
| ClinicalTrials.gov Identifier: | NCT01005511 History of Changes |
| Other Study ID Numbers: | TMD-01 |
| Study First Received: | October 30, 2009 |
| Last Updated: | June 7, 2011 |
| Health Authority: | Denmark: The Danish National Committee on Biomedical Research Ethics Denmark: Danish Dataprotection Agency |
Keywords provided by Medotech A/S:
|
Bruxism |
Additional relevant MeSH terms:
|
Bruxism Sleep Bruxism Tooth Diseases Stomatognathic Diseases |
Parasomnias Sleep Disorders Nervous System Diseases Mental Disorders |
ClinicalTrials.gov processed this record on May 23, 2013